Psoriasis (PsO)GHSPNCT07634016
Global Healthcare Study on Psoriasis
An observational study of Psoriasis (PsO), run by Julia Tatjana Maul at 1 site in Switzerland.
Trial summary
The Global Healthcare Study on Psoriasis (GHSP) is an international, multicenter observational study hosted by the University of Zurich (UZH) investigating healthcare access, treatment patterns, disease severity, and quality of life in patients with psoriasis. Read more about this study
- Who is it for?
- Ages 14 years and older
- Conditions the study is for
- Psoriasis (PsO)
- How many people
- 9,600 participants
- Where
- 1 siteSwitzerland
- Study dates
- 1 Jan 2025to 31 Dec 2029
- How long will I take part?
- 5 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 14 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patient populations across world regions seen for psoriasis.
Who may be able to join
- Signed General Consent Form, or equivalent document
- Confirmed diagnosis of Psoriasis
Who cannot join
- Inability to provide informed consent.
- Datasets with ambiguous or unclear diagnosis.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Switzerland1 site, 1 recruiting
- Recruiting
University of Zurich
Zurich
Julia-Tatjana Maul, +41 76 441 51 09, julia-tatjana.maul@uzh.ch
About this study
The Global Healthcare Study on Psoriasis (GHSP) is an international, multicenter observational study hosted by the University of Zurich (UZH) investigating healthcare access, treatment patterns, disease severity, and quality of life in patients with psoriasis. The study collects standardized clinical data from routine medical records to identify disparities in healthcare delivery and outcomes across different healthcare systems.
Read the detailed description
The study employs a combined retrospective and prospective design, collecting data from routine clinical care and medical records spanning from January 2020 through the study conclusion.
- Conditions
- Psoriasis (PsO)
- Medical subject headings
- Psoriasis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Global Healthcare Study on Psoriasis | Patients with Psoriasis |
What is being measured
The primary outcome is the main question the study is designed to answer.
Psoriasis Area Severity Index (PASI)
Composite clinician-assessed measure of psoriasis severity based on erythema, scaling, thickness, and affected body surface area; total score ranges from 0 to 72, with higher scores indicating more severe disease.
Measured: Baseline and follow-up visits every 6-12 months for up to 5 years.
Secondary outcomes (5)
Dermatology Life Quality Index (DLQI)
Patient-reported measure of dermatology-specific quality of life; total score ranges from 0 to 30, with higher scores indicating greater impairment.
Measured: Baseline and follow-up visits every 6-12 months for up to 5 years.
Nail Psoriasis Severity Index (NAPSI)
Clinician-assessed measure of nail psoriasis severity based on nail matrix and nail bed involvement; scores range from 0-80 for fingernails and 0-80 for toenails; total score ranges from 0-160, with higher scores indicating more severe nail disease.
Measured: Baseline and follow-up visits every 6-12 months for up to 5 years.
Numerical Rating Scale (NRS) for disease severity
Patient-reported assessment of psoriasis severity on a numerical rating scale from 0 (no disease) to 10 (most severe disease imaginable).
Measured: Baseline and follow-up visits every 6-12 months for up to 5 years.
Physician Global Assessment (PGA)
Clinician-assessed global measure of psoriasis severity on a scale from 0 (clear) to 4 (severe).
Measured: Baseline and follow-up visits every 6-12 months for up to 5 years.
Body Surface Area (BSA)
Percentage of total body surface area affected by psoriasis, ranging from 0% to 100%.
Measured: Baseline and follow-up visits every 6-12 months for up to 5 years.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Jun 2026
- Study start1 Jan 2025
- Primary completion31 Dec 2029 (estimated)
- Study completion31 Dec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Psoriasis (PsO)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 9,600 participants (estimated)
- Target duration
- 5 Years
Sponsor and investigators
- Lead sponsor
- Julia Tatjana Maul
- Sponsor type
- University, hospital or other
- Collaborators
- University of Zurich, University Hospital, Zürich
- Responsible party
- Sponsor-investigator, Julia Tatjana Maul, University of Zurich
- Investigators
- Julia-Tatjana Maul, Prof. Dr. med., Principal investigator, University of Zurich
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07634016
- Sponsor's protocol ID
- 2020-00002
- Acronym
- GHSP
- Status last verified
- Sep 2026
- First submitted
- 2 Jun 2026
- Last updated
- 28 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Maul JT, Maul LV, Didaskalu JA, Valenzuela F, Romiti R, Peterson H, Korouri E, Novoa F, Oon HH, Zheng M, Wu JJ, Thyssen JP, Egeberg A, Armstrong AW, Nielsen ML. Correlation between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis: A Cross-sectional Global Healthcare Study on Psoriasis. Acta Derm Venereol. 2024 Mar 12;104:adv20329. doi: 10.2340/actadv.v104.20329.
PubMed 38470165Valenzuela F, De La Cruz C, Lecaros C, Fernandez J, Hevia G, Maul LV, Thyssen JP, Vera-Kellet C, Egeberg A, Armijo D, Pizarro C, Riveros T, Correa H, Guglielmetti A, Didaskalu JA, Wu JJ, Griffiths CEM, Romiti R, Maul JT. Comorbidities in Chilean patients with psoriasis: a Global Healthcare Study on Psoriasis. Clin Exp Dermatol. 2022 Dec;47(12):2234-2241. doi: 10.1111/ced.15384. Epub 2022 Oct 28.
PubMed 35988043Maul JT, Frohlich F, Maul LV, Stunnenberg R, Valenzuela F, De La Cruz C, Vera-Kellet C, Armijo D, Cesar WG, Carvalho A, Didaskalu JA, Graf N, Egeberg A, Wu JJ, Thyssen JP, Romiti R, Griffiths CEM. Access to psoriasis treatment in Brazil and Chile: A cross-sectional multicentre Global Healthcare Study on Psoriasis. Br J Dermatol. 2023 Mar 30;188(4):533-541. doi: 10.1093/bjd/ljac128.
PubMed 36653920Korouri E, Jeong C, Peterson H, Valenzuela F, Romiti R, Didaskalu JA, Egeberg A, Oon HH, Maul LV, Kingston P, Lee K, Huang MY, Yee D, Artiga K, Aguero R, Maul JT, Armstrong AW. Global Comparison of COVID-19 Vaccination Rates among Psoriasis Patients. Life (Basel). 2024 Oct 13;14(10):1297. doi: 10.3390/life14101297.
PubMed 39459597Goh E, Nielsen ML, Maul LV, Didaskalu JA, Chularojanamontri L, Guevara BEK, Ji M, Zheng M, Maul JT, Oon HH. Clinical Characteristics and Treatment Patterns of Psoriasis in Asia and Switzerland: Results of the Multicentre Global Healthcare Study on Psoriasis (GHSP). Int J Dermatol. 2026 Jun;65(6):1195-1202. doi: 10.1111/ijd.70183. Epub 2025 Nov 30.
PubMed 41319042
Study at a glance
From the registry record, last updated by the sponsor on 28 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Global Healthcare Study on Psoriasis
- ClinicalTrials.gov ID
- NCT07634016
- Acronym / sponsor ID
- GHSP / 2020-00002
- Conditions
- Psoriasis (PsO)
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 9,600 participants (estimated)
- Lead sponsor
- Julia Tatjana MaulUniversity, hospital or other
- Collaborators
- University of Zurich, University Hospital, Zürich
- Study start
- 1 Jan 2025 (actual)
- Primary completion
- 31 Dec 2029 (estimated)
- Study completion
- 31 Dec 2029 (estimated)
- First posted
- 8 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The Global Healthcare Study on Psoriasis (GHSP) is an international, multicenter observational study hosted by the University of Zurich (UZH) investigating healthcare access, treatment patterns, disease severity, and quality of life in patients with psoriasis. The study collects standardized clinical data from routine medical records to identify disparities in healthcare delivery and outcomes across different healthcare systems.
Detailed description
The study employs a combined retrospective and prospective design, collecting data from routine clinical care and medical records spanning from January 2020 through the study conclusion.
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Target follow-up
- 5 Years
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Global Healthcare Study on Psoriasis | – | –Patients with Psoriasis |
Who may qualify
- Ages
- 14 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patient populations across world regions seen for psoriasis.
Key inclusion criteria (2 listed)
- Signed General Consent Form, or equivalent document
- Confirmed diagnosis of Psoriasis
Key exclusion criteria (2 listed)
- Inability to provide informed consent.
- Datasets with ambiguous or unclear diagnosis.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Psoriasis Area Severity Index (PASI)
Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.
Composite clinician-assessed measure of psoriasis severity based on erythema, scaling, thickness, and affected body surface area; total score ranges from 0 to 72, with higher scores indicating more severe disease.
5 secondary outcomes
Dermatology Life Quality Index (DLQI)
Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.
Nail Psoriasis Severity Index (NAPSI)
Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.
Numerical Rating Scale (NRS) for disease severity
Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.
Physician Global Assessment (PGA)
Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.
Body Surface Area (BSA)
Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Sep 2026.
- Results publication: PubMed 38470165Maul JT, Maul LV, Didaskalu JA, Valenzuela F, Romiti R, Peterson H, Korouri E, Novoa F, Oon HH, Zheng M, Wu JJ, Thyssen JP, Egeberg A, Armstrong AW, Nielsen ML. Correlation between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis: A Cross-sectional Global Healthcare Study on Psoriasis. Acta Derm Venereol. 2024 Mar 12;104:adv20329. doi: 10.2340/actadv.v104.20329.
- Results publication: PubMed 35988043Valenzuela F, De La Cruz C, Lecaros C, Fernandez J, Hevia G, Maul LV, Thyssen JP, Vera-Kellet C, Egeberg A, Armijo D, Pizarro C, Riveros T, Correa H, Guglielmetti A, Didaskalu JA, Wu JJ, Griffiths CEM, Romiti R, Maul JT. Comorbidities in Chilean patients with psoriasis: a Global Healthcare Study on Psoriasis. Clin Exp Dermatol. 2022 Dec;47(12):2234-2241. doi: 10.1111/ced.15384. Epub 2022 Oct 28.
- Results publication: PubMed 36653920Maul JT, Frohlich F, Maul LV, Stunnenberg R, Valenzuela F, De La Cruz C, Vera-Kellet C, Armijo D, Cesar WG, Carvalho A, Didaskalu JA, Graf N, Egeberg A, Wu JJ, Thyssen JP, Romiti R, Griffiths CEM. Access to psoriasis treatment in Brazil and Chile: A cross-sectional multicentre Global Healthcare Study on Psoriasis. Br J Dermatol. 2023 Mar 30;188(4):533-541. doi: 10.1093/bjd/ljac128.
- Results publication: PubMed 39459597Korouri E, Jeong C, Peterson H, Valenzuela F, Romiti R, Didaskalu JA, Egeberg A, Oon HH, Maul LV, Kingston P, Lee K, Huang MY, Yee D, Artiga K, Aguero R, Maul JT, Armstrong AW. Global Comparison of COVID-19 Vaccination Rates among Psoriasis Patients. Life (Basel). 2024 Oct 13;14(10):1297. doi: 10.3390/life14101297.
- Results publication: PubMed 41319042Goh E, Nielsen ML, Maul LV, Didaskalu JA, Chularojanamontri L, Guevara BEK, Ji M, Zheng M, Maul JT, Oon HH. Clinical Characteristics and Treatment Patterns of Psoriasis in Asia and Switzerland: Results of the Multicentre Global Healthcare Study on Psoriasis (GHSP). Int J Dermatol. 2026 Jun;65(6):1195-1202. doi: 10.1111/ijd.70183. Epub 2025 Nov 30.
- Individual participant dataSharing planned: No
Related trials for Psoriasis (PsO)
Not yet recruiting
Definition of Novel Optoacoustic Biomarkers of Psoriasis and Psoriatic Arthritis
Psoriasis (PsO), Psoriasis Arthritis
Recruiting
A Prospective, Interventional, Exploratory Study Evaluating the Efficacy of Small-Molecule Compound XJH05 Ointment in the Treatment of Plaque Psoriasis
Psoriasis, Psoriasis (PsO)
RecruitingObservational study
Retinal Capillary Vessel Density and Foveal Avascular Zone Size in Patients With Psoriatic Arthritis: A Case-Control Study.
Arthritic Psoriasis, Psoriasis (PsO)
RecruitingObservational study
A Study to Assess Deucravacitinib Safety in Pregnancy
Psoriasis (PsO)
RecruitingObservational study
Impact of Tildrakizumab on Patient Reported Outcomes in Patients With Moderate-to-severe Psoriasis in Canada
Psoriasis (PsO), Moderate to Severe Psoriasis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Julia-Tatjana Maul, Prof. Dr. med. principal investigator
University of Zurich
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Psoriasis (PsO), run by Julia Tatjana Maul at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 28 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Julia-Tatjana Maul, Prof. Dr. med. (+41 76 441 51 09, julia-tatjana.maul@uzh.ch), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Psoriasis Area Severity Index (PASI) (time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07634016, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Sep 2026; AzTrials last refreshed its copy on 29 Oct 2026.